NCCN VERSION 2 2015

NCCN Guidelines Version 2.2015 Breast Cancer

NCCN Guidelines Index Breast Cancer Table of Contents Discussion

Reproduction Update 2009;15:323-339. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19174449 .

384. Garber K. Tamoxifen pharmacogenetics moves closer to reality. J Natl Cancer Inst 2005;97:412-413. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15770000 . 385. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30-39. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15632378 . 386. Henry NL, Stearns V, Flockhart DA, et al. Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. 387. Ahern TP, Pedersen L, Cronin-Fenton DP, et al. No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. Cancer Epidemiol Biomarkers Prev 2009;18:2562-2564. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19690182 . 388. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-497. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16079372 . 389. Li CI, Daling JR, Porter PL, et al. Relationship between potentially modifiable lifestyle factors and risk of second primary contralateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancer. J Clin Oncol 2009;27:5312-5318. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19738113 . 390. Pierce JP, Stefanick ML, Flatt SW, et al. Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. J Clin Oncol 2007;25:2345-2351. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17557947 . 391. Hickey M, Peate M, Saunders CM, Friedlander M. Breast cancer in young women and its impact on reproductive function. Human Am J Psychiatry 2008;165:1251-1255. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18829880 .

392. Moran MS, Colasanto JM, Haffty BG, et al. Effects of breast- conserving therapy on lactation after pregnancy. Cancer J 2005;11:399- 403. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16259870 . 393. Eubank WB, Mankoff D, Bhattacharya M, et al. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. AJR Am J Roentgenol 2004;183:479-486. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15269044 . 394. Moon DH, Maddahi J, Silverman DH, et al. Accuracy of whole- body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 1998;39:431-435. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9529287 . 395. Arslan C, Sari E, Aksoy S, Altundag K. Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature. Expert Opin Ther Targets 2011;15:21- 30. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21105765 . 396. Pusztai L, Viale G, Kelly CM, Hudis CA. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. 397. Bogina G, Bortesi L, Marconi M, et al. Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss. Virchows Arch 2011;459:1-10. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21643691 . 398. Fabi A, Di Benedetto A, Metro G, et al. HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. Clin Cancer Res 2011;17:2055-2064. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21307144 . Oncologist 2010;15:1164-1168. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21041379 .

Version 2.2015, 03/11/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. MS-95